Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation

Transplant International

Volumn 27, Issue 3, 2014, Pages 280-289

  Gerlach, Undine A ^a   Lachmann, Nils ^a   Sawitzki, Birgit ^a   Arsenic, Ruza ^a   Neuhaus, Peter ^a   Schoenemann, Constanze ^a   Pascher, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antibody mediated rejection; donor specific anti HLA antibodies; intestine; multivisceral clinical

Indexed keywords

ALLOANTIBODY; HLA ANTIGEN;

ADULT; ANTIBODY SPECIFICITY; BIOSYNTHESIS; DONOR; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; TRANSPLANTATION; YOUNG ADULT;

ADULT; ANTIBODY SPECIFICITY; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; INTESTINES; ISOANTIBODIES; MALE; MIDDLE AGED; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY; YOUNG ADULT;

EID: 84894055592     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12250     Document Type: Article

References (46)

1. Mazariegos GV, Steffick DE, Horslen S, et al,. Intestine transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1020.
2. Dick AA, Horslen S,. Antibody-mediated rejection after intestinal transplantation. Curr OPin Organ Transplant 2012; 17: 250.
3. Abu-Elmagd KM, Wu g, Costa G, et al,. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver. Am J Transplant 2012; 12: 3047.
4. Dunn TB, Noreen H, Gillingham K, et al,. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132.
5. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al,. Frequency and clinical implications of development of donor-specific and non donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804.
6. Mao Q, Terasaki PI, Cai J, et al,. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five year longitudinal study. Am J Transplant 2007; 7: 864.
7. Lachmann N, Terasaki PI, Budde K, et al,. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
8. Lefaucheur C, Nochy D, Hill GS, et al,. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832.
9. Gloor J, Cosio F, Lager DJ, et al,. The spectrum of antibody mediated renal allograft injury: implications for treatment. Am J Transplant 2008; 8: 1367.
10. Everly MJ, Everly JJ, Arend LJ, et al,. Reducing de novo donorspecific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
11. Loupy A, Suberbielle-Boissel C, Hill GS, et al,. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561.
12. Lefaucheur C, Loupy A, Hill GS, et al,. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
13. Ruiz P, Garcia M, Pappas P, et al,. Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization. Am J Transplant 2003; 3: 43.
14. Wu T, Abu-Elmagd K, Bond G, et al,. A clinicopathologic study of isolated intestinal allografts with preformed IgG lymphocytotoxic antibodies. Human Pathol 2004; 35: 1332.
15. Ruiz P, Carreno M, Weppler D, et al,. Immediate antibody-mediated (hyperacute) rejection in smal-bowel transplantation and relationship to cross-match status and donor-specific C4d-binding antibodies: case report. Transplantation Proc 2010; 42: 95.
16. Tschernia A, LeLeiko NS, Grima K, et al,. Anti-HLA antibody removal by extracorporeal immunoadsorption in two hyperimmunized pediatric pateints awaiting hepatointestinal transplantation. Transplant Proc 2002; 34: 900.
17. Gonzalez-Pinto IM, Tzakis AG, Tsai H-L, et al,. Association between panel reactive antibodies and acute small bowel rejection: analysis of a series of 324 intestinal transplants. Transplant Proc 2010; 42: 4269.
18. Kato T, Mizutani K, Terasaki P, et al,. Association of emergence of HLA antibody and acute rejection in intestinal transplant recipients: a possible evidence of acute hunoral sensitization. Transplant Proc 2006; 38: 1735.
19. Troxell ML, Higgins JP, Kambham N, et al,. Evaluation of C4d-staining in liver and small intestine allografts. Arch Pathol Lab Med 2006; 130: 1489.
20. Gloor JM, Sethi S, Stegall MD, et al,. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124.
21. Cosio FG, Gloor JM, Sethi S, et al,. Transplant glomerulopathy. Am J Transplant 2008; 8: 492.
22. Sis B, Mengel M, Haas M, et al,. Banff '09meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.
23. Hill GS, Nochy D, Bruneval P, et al,. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22: 975.
24. Liefeldt L, Brakemeier S, Glander P, et al,. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transpl 2012; 12: 1192.
25. Lee PC, Zhu L, Terasaki PI, Everly MJ,. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
26. Faguer S, Kamar N, Guilbeaud-Frugier C, et al,. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277.
27. Perry DK, Pollinger HS, Burns JM, et al,. Two novel assays of alloantibody-screting cells demonstrating resistance to desensitization with ivIG and rATG. Am J Transplant 2008; 8: 133.
28. Ramos EJ, Pollinger HS, Stegal MD, et al,. The effect of desensitization protocols on human splenic B-cell population in vivo. Am J Transplant 2007; 7: 402.
29. Everly MJ, Everly JJ, Susskind B, et al,. Bortzomib provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection. Transplantation 2008; 86: 1754.
30. Gerlach UA, Schoenemann C, Pascher A, et al,. Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib. Transpl Int 2011; 24: e43. Epub 2010 Dec 14.
31. Reutzel-Selke A, Hartmann J, Pratschke J, et al,. Cold Ischemia does not interfere with tolerance induction. Transplantation 2009; 87: 1116.
32. Miller EA, Ernst JD,. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. JCI 2009; 119: 1079.
33. Duquesnoy RJ,. Clinical usefulness of HLA Matchmaker in HLA epitope matching for organ transplantation. Curr Opin Immunol 2008; 20: 594.
34. Ruiz P, Bagni A, Brown R, et al,. Histological criteria for the identification of acute cellular rejection in human small bowel allografts: results of the pathology workshop at the VIII International Small Bowel Transplant Symposium. Transplant Proc. 2004; 36: 335.
35. Fehr T, Gaspert A,. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int 2013; 26: 535.
36. Riethmuller S, Ferrari-Lacraz S, Muller MK, et al,. Donor-specific antibody levels and three generations of cross-matches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010; 90: 160.
37. Bruns H, Meinken C, Schauenberg P, et al,. Anti-TNF immunotherapy reduces CD8 + T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest. 2009; 119: 1167.
38. Karampetsou MP, Andonopoulos AP, Liossis SN,. Treatment with TNFα blockers induces phenotypical and functional aberrations in peripheral B cells. Clin Immunol. 2011; 140: 8.
39. Sánchez-Fructuoso AI, Santiago JL, Pérez-Flores I, et al,. De novo anti-HLA antibodies in renal allograft recipients: a cross-section study. Transplant Proc 2010; 42: 2874.
40. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al,. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
41. Walsh RC, Everly JJ, Brailey P, et al,. Proteasome-inhibitor based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277.
42. Patey-Mariaud de Serre N, Canioni D, Lacaille F, et al,. Evolution of C4d deposition and circulating antibody in small bowel transplantation. Am J Transplant 2008; 8: 1290.
43. Abu-Elmagd K, Costa G, Bond GJ, et al,. Five hundred intestinal and multivisceral transplantations at a single center. Ann Surg 2009; 250: 567.
44. Rana A, Robles S, Russo MJ, et al,. The combined organ effect: protection against rejection? Ann Surg 2008; 248: 871.
45. http://www.intestinaltransplant.org (accessed May 20, 2012).
46. Martin L, Guignier F, Bocrie O, et al,. Detection of anti-HLA antibodies with flow cytometry in needle core biopsies of renal transplants recipients with chronic allograft nephropathy. Transplantation 2005; 79: 1459.